Mainz Biomed B.V.
MYNZ · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | -0.2% | 69% | -8.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $1 | $0 | $0 |
| % Margin | 64.3% | 56.9% | 34.4% | 30.8% |
| R&D Expenses | $6 | $10 | $4 | $0 |
| G&A Expenses | $8 | $13 | $18 | $8 |
| SG&A Expenses | $13 | $17 | $23 | $9 |
| Sales & Mktg Exp. | $5 | $4 | $5 | $1 |
| Other Operating Expenses | $1 | $0 | -$0 | -$0 |
| Operating Expenses | $19 | $27 | $26 | $10 |
| Operating Income | -$19 | -$27 | -$26 | -$10 |
| % Margin | -2,091.2% | -2,975.5% | -4,990.6% | -1,684.4% |
| Other Income/Exp. Net | -$3 | $0 | $0 | -$2 |
| Pre-Tax Income | -$22 | -$26 | -$26 | -$12 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$22 | -$26 | -$26 | -$12 |
| % Margin | -2,421.8% | -2,936.5% | -4,992.2% | -2,024.8% |
| EPS | -22.36 | -1.62 | -1.87 | -1.67 |
| % Growth | -1,280.2% | 13.4% | -12% | – |
| EPS Diluted | -22.36 | -1.62 | -1.87 | -1.67 |
| Weighted Avg Shares Out | 1 | 16 | 14 | 7 |
| Weighted Avg Shares Out Dil | 1 | 16 | 14 | 7 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$20 | -$25 | -$26 | -$11 |
| % Margin | -2,187.8% | -2,793.1% | -4,853.6% | -1,953.9% |